# MONARCH 1 (NCT02102490)

> A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02102490
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Eli Lilly and Company
- Conditions: Metastatic Breast Cancer
- Interventions: Abemaciclib
- Enrollment: 132
- Primary outcome: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

## Commentary we found

- Podcasts: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=monarch-1-nct02102490